Retatrutide vs. tirzepatide: which is better for weight control?

Tirzepatide and retatrutide are both weight loss medications, but they work differently and are at very different stages of development.

If you're researching retatrutide vs. tirzepatide and are wondering whether retatrutide’s worth waiting for, here's what the current evidence actually shows.

Based on available trial data, retatrutide appears to produce greater average weight loss than tirzepatide. However, the two have not been directly compared in a head-to-head trial, and retatrutide is not yet approved for use.

Tirzepatide is currently available with a well-established safety record and approval from the US Food and Drug Administration (FDA). Retatrutide is not available to the public and is still being studied in clinical trials. Its commercial availability will depend on the outcome of ongoing trials and FDA review.

Fastest-working GLP-1 for faster weight loss

See if you qualify

Based on data from separate clinical trials, both medications can produce significant weight loss, but retatrutide has shown higher average results than tirzepatide.

In a phase 3 TRIUMPH-4 trial , people taking 12 mg of retatrutide lost an average of 28.7% of their body weight at 68 weeks. For someone starting at 250 pounds, that translates to roughly 72 pounds lost.

• This study enrolled 445 adults with obesity or overweight and knee osteoarthritis. 

• After 68 weeks, participants lost an average of 26.4% of their body weight on 9 mg and 28.7% on 12 mg, compared with 2.1% with placebo. Most people also experienced a substantial reduction in knee pain.

In a retatrutide phase 2 trial, people taking 12 mg of the medication lost an average of up to 24.2% of their body weight at 48 weeks, compared with 2.1% on placebo. 

• The study involved 338 adults with obesity or overweight and at least one weight-related condition (but not diabetes). 

• At 48 weeks, all participants on 8 mg and 12 mg of retatrutide lost at least 5% of their body weight, and 83% on the 12 mg dose lost at least 15%.

In comparison, tirzepatide's best results were found in a phase 3 trial that showed the drug could lead to a weight loss of up to 20.9% at 72 weeks — about 52 pounds for someone starting at 250 pounds. 

• These results come primarily from SURMOUNT-1, a large phase 3 trial of 2,539 adults with obesity or overweight and at least one weight-related complication, who did not have diabetes.

• At 72 weeks, people lost an average of 15%, 19.5%, and 20.9% of their body weight on doses of 5 mg, 10 mg, and 15 mg, respectively, compared with 3.1% on placebo.

It’s worth mentioning that these results aren’t directly comparable. The trials enrolled different populations, ran for different durations, and used different designs. Individual results will always vary based on starting weight, dose, adherence, and lifestyle factors.

Tirzepatide is a once-weekly injection that targets two hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 GLP-1. It’s available under two brand names: 

• Mounjaro was approved in 2022 to improve blood sugar control in adults with type 2 diabetes.

• Zepbound was approved in 2023 for chronic weight management in adults with obesity or for overweight and at least one weight-related condition. It’s also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide is also sometimes prescribed off-label for weight loss in people who don't meet the formal criteria for these approved uses. Because tirzepatide is approved and widely available, it has accumulated a large amount of real-world safety and efficacy data.

Retatrutide, by contrast, is still being studied in clinical trials and doesn’t yet have comparable real-world data.

Retatrutide is an investigational once-weekly injection that targets three hormone receptors: GIP, GLP-1, and glucagon (GCG). It isn’t FDA-approved and isn’t commercially available yet. All data on retatrutide comes from clinical trials.

Phase 2 trial have been completed and published. The phase 3 TRIUMPH program is underway, with the first positive results from the TRIUMPH-4 trial announced in December 2025.

Retatrutide is not expected to be available for prescription use until FDA review and approval are complete.

Both medications target at least two hormone receptors at once, but they work through different mechanisms. Here’s how they compare across the factors that matter most.

* Retatrutide dosing shown here reflects doses studied in clinical trials. Because retatrutide is still investigational, dosing has not been finalized for clinical use. Official dosage guidance would be determined during FDA review.

Both retatrutide and tirzepatide target receptors that control hunger, blood sugar, and fat storage. But retatrutide adds a third receptor to the mix, which may explain the difference in weight loss results seen in trials so far.

How tirzepatide works

Tirzepatide works by activating two receptors that play a role in appetite and blood sugar control. By targeting both the GLP-1 and GIP receptors simultaneously, tirzepatide creates a broader effect than medications that target only one.

It reduces feelings of hunger and food cravings and makes you feel fuller after eating. It also slows digestion, so food moves through the digestive system more slowly. This keeps you feeling satisfied for longer after eating.

Tirzepatide improves the production of insulin in your pancreas and lowers glucagon, a hormone that raises blood sugar. Because it acts on multiple mechanisms in your body, it works differently from older weight loss medications.

How retatrutide works

Retatrutide does everything tirzepatide does, since it activates two of the same receptors, but additionally, it also activates the glucagon receptor as a third target.

This additional mechanism may be a key reason why retatrutide appears to produce even greater weight loss, though this is based on trial data and not an approved use.

Glucagon is a hormone that signals the liver to release stored energy, and in animal studies has been shown to stimulate thermogenesis (heat production) in fat tissue, but this effect has not been clearly confirmed in humans.

By activating the glucagon receptor alongside GIP and GLP-1, retatrutide may support greater fat breakdown and energy expenditure, an effect that goes beyond what GLP-1 activation alone is known to achieve.

Both tirzepatide and retatrutide share a similar side effect profile, with gastrointestinal symptoms being the most commonly reported. Most of these effects are temporary and tend to improve as your body adjusts to the medication.

Tirzepatide side effects

The most common side effects of tirzepatide are gastrointestinal, particularly during dose escalation. This includes nausea, diarrhea, vomiting, constipation, and decreased appetite. Some people have also noticed hypersensitivity and injection site reactions.

Side effects of Zepbound and Mounjaro are similar, typically related to the dose you’re taking, and tend to improve over time.

Like other medications in this category, tirzepatide carries an FDA boxed warning about a possible risk of thyroid C-cell tumors, based on animal studies.

It isn’t known whether tirzepatide causes thyroid tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide isn’t recommended for anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN 2).

Retatrutide side effects

Based on phase 2 trial data, retatrutide has a similar gastrointestinal side effect profile to tirzepatide. Nausea, diarrhea, vomiting, and constipation were the most frequently reported adverse events in the trial, and their intensity was clearly linked to higher doses.

More recent data from TRIUMPH-4 remained consistent with nausea, diarrhea, constipation, and vomiting.

Dysesthesia (unusual skin sensations) has been reported with both medications. But this side effect has occurred at higher rates with retatrutide than with tirzepatide in clinical trials.

In clinical trials, heart rate increases were also observed with retatrutide and tended to rise, depending on dose, early in treatment before declining later in the study period.

It’s important to note that retatrutide's full safety profile is still developing, as the clinical trial results continue to be analyzed.

Both medications follow a gradual dose escalation schedule, starting low and increasing over several weeks to help your body adjust. This retatrutide vs. tirzepatide dosage chart gives you a side-by-side look at how the two compare.

* Retatrutide dosing shown here reflects doses studied in clinical trials. Because retatrutide is still investigational, dosing has not been finalized for clinical use. Any approved schedule would be determined during FDA review.

Tirzepatide's dosing schedule is established by the FDA-approved prescribing label. Retatrutide dosing varied depending on the treatment people were assigned to in the trials. Its dosing hasn’t been finalized for clinical use, and any approved schedule would be determined at the time of FDA review.

If you're looking for a medication you can start today (if eligible), tirzepatide is the only option between the two. It’s FDA-approved and commercially available, with an established safety record built from large clinical trials and real-world use.

Retatrutide may eventually become available, but FDA approval is still pending the completion of the TRIUMPH program.

A healthcare provider can help you evaluate whether you're eligible for tirzepatide now, discuss your personal health history and risk profile, and keep you informed as more retatrutide data becomes available.

The decision to start, switch, or wait is one best made with professional guidance.

See if you qualify

Both tirzepatide and retatrutide are developed by the same company and work by targeting specific hormone receptors, but they differ in important ways. Here's what to keep in mind:

• Tirzepatide is available now as two brand-name drugs. Zepbound is FDA-approved for weight loss and sleep apnea and Mounjaro is approved for type 2 diabetes. Tirzepatide has an established safety profile and has shown an average weight loss of up to 20.9% in trials.

• Retatrutide is still being studied. In addition to targeting GLP-1 and GIP like tirzepatide, retatrutide also targets glucagon receptors, which may account for its higher average weight loss figures of up to 28.7% in the phase 3 TRIUMPH-4 trial. But it’s not currently FDA-approved or commercially available.

• The two have not been directly compared. Trial data suggest retatrutide may produce greater average weight loss, but differences in trial design, population, and duration make a direct comparison to tirzepatide difficult.

• Side effects of tirzepatide and retatrutide seem to be similar. Both medications primarily cause GI symptoms, particularly when the dose is being increased. 

If your research into retatrutide vs. tirzepatide has you ready to explore your options today, Ro makes it easy to access FDA-approved weight loss medications like Zepbound and Wegovy (if eligible), with the support of a licensed healthcare provider.